John Hohneker Buys Shares of AVBP
John Hohneker purchased 13,562 shares of AVBP on June 18, 2026.
Key Points
- John Hohneker purchased 13,562 shares of AVBP on June 18, 2026, with no planned transaction reported.
- AVBP shares traded near $31.74 on Tuesday, with various institutional investors adjusting their positions.
- Analysts like Truist Securities and Citigroup maintain a 'buy' rating, with price targets ranging from $33 to $50.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, John Hohneker purchased 13,562 shares of AVBP. This insider transaction was not part of a pre-planned trading program and reflects a direct acquisition of shares.
Other Institutional Activity in AVBP
Several institutional investors have recently adjusted their holdings in AVBP. Suvretta Capital Management, LLC increased its position by 295,048 shares, bringing its total to over 4.4 million shares valued at approximately $101.5 million. Infinitum Asset Management, LLC added 25,000 shares, reaching a total of around 4.1 million shares worth $95.7 million. Meanwhile, FMR LLC reduced its stake by 687,440 shares, leaving it with about 3 million shares valued at $69.6 million. BlackRock, Inc. also grew its holdings by 157,463 shares to a total of 2.5 million shares, valued at approximately $58.4 million.
ArriVent BioPharma, Inc. Stock Up 8.4%
Shares of AVBP traded near $31.74 on Tuesday. The stock has been a focus for institutional investors, with BlackRock and Suvretta Capital Management making notable adjustments to their positions. Analysts maintain a positive outlook on AVBP, with several firms reiterating their 'buy' ratings.
$AVBP stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at ArriVent BioPharma, Inc.
In addition to John Hohneker, several other insiders purchased shares on June 18, 2026. Chris Nolet, Kristine Peterson, and Merdad Parsey each bought 13,562 shares. Earlier this year, on February 2, James Paul Kastenmayer, General Counsel, and Winston Kung, Chief Financial Officer, made significant purchases of 130,000 and 140,000 shares, respectively.
Analysts Set New Price Targets
Analysts remain optimistic about AVBP's prospects. On May 29, 2026, Truist Securities maintained a 'buy' rating with a price target of $45. Citigroup has consistently supported a 'buy' rating, with targets ranging from $33 to $45 in recent months. The consensus among analysts is a 'buy' recommendation, with the average price target reflecting a positive outlook.
Bottom Line
John Hohneker's recent purchase of AVBP shares adds to the insider buying activity, indicating a potential vote of confidence in the company's future. Institutional investors have also been active, with some increasing and others reducing their stakes. Analysts continue to support a 'buy' rating, suggesting optimism about AVBP's performance. As always, these insights are based on past filings and transactions, and the actual current holdings may differ.
Get ArriVent BioPharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AVBP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.